IN VIVO SELECTION OF LIGANDS FOR TARGETED THERAPY

用于靶向治疗的体内配体选择

• 批准号: 7605791
• 负责人: DAVID N KRAG
• 金额: $ 0.08万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605791
• 关键词: Address; Antineoplastic Agents; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Future; Grant; Institution; Ligands; Malignant Neoplasms; Methods; Peptides; Purpose; Research; Research Personnel; Resources; Source; Tissues; United States National Institutes of Health; cancer cell; design; in vivo

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to develop a method to substantially increase the dose of anticancer drugs directly to a cancer while decreasing the dose to normal body tissue. We propose to develop a tag, a peptide, to be added to the anticancer drug, which would allow the anticancer drug to be delivered and concentrated at cancer cells. The purpose of this study is to develop the tag that will attach to the "address" of cancer cells. In a future study the targeting agent (tag) will be designed to deliver anticancer drugs directly to the address of the cancer cells. We propose to intravenously inject several million different tags. A small piece of the cancer is removed and the tags that have found their way to the cancer cells and are able to stick at the address of cancer cells will be determined.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是开发一种方法，以大幅增加直接用于癌症的抗癌药物剂量，同时减少用于正常身体组织的剂量。 我们建议开发一种标签，一种肽，添加到抗癌药物中，这将允许抗癌药物被递送并集中在癌细胞中。 这项研究的目的是开发将附着在癌细胞“地址”上的标签。 在未来的研究中，靶向剂（标签）将被设计为将抗癌药物直接递送到癌细胞的地址。 我们建议静脉注射几百万种不同的标签。 切除一小块癌症，并确定已经找到癌细胞并能够粘附在癌细胞地址的标签。